China R&D Reader

All global large pharmaceutical companies have R&D centers in China, but they  are  using different models in its R&D effort in China.
Top R&D leaders from global pharmaceutical companies, including Pfizer, Eli Lily, Roche, AstraZeneca, Merck explained their R&D models, and learning from the past years, in a roundtable discussion in the Asia Pharma R&D Leaders [...]

Millipore Corporation, a leading life science company, and Merck & Co. Inc., a global pharmaceutical and chemicals company, entered into a definitive agreement under which Merck will acquire all outstanding shares of common stock of Millipore for US$107 per share in cash, or a total transaction value, including net debt, of approximately €5.3 billion (US$7.2 [...]

The rapid growth of China’s economy is reflected in the dramatic rate of development observed in the nation’s biotech and pharmaceutical industry. Currently, there are more than 300 contract research organizations(CROs) and 5,000 pharmaceutical companies in China. The gross domestic product of China’s medical and pharmaceutical industry exceeded US$140 billion in 2008, compared to only [...]

Three of big pharma’s biggest companies, Merck, Lilly and Pfizer, have banded together to create an Asian not-for-profit company that will construct a pharmacogenomic cancer database in Singapore. The database will compile its information using 2,000 tissue samples from patients with lung and gastric cancer. The information will be made available to researchers with the [...]

At the beginning of 2009, IPO activity was at a standstill. But as the year progressed, and the threat of a complete financial disaster receded, a few companies managed to complete transactions that made them publicly owned entities, including several representatives of the China life science sector. We looked at how they fared, noticing a [...]

2009年世界制药巨头紧抓着我国医改之政策，纷纷抢占我国医药市场份额。寄望业内人士要保持足够的警醒，若国内市场我们不再想法保全的话，未来几年，国内医药市场也将无立足之地。

Syngenta Biotechnology, a division of the Swiss giant agribusiness company Syngenta (NYSE: SYT), has begun construction of an R&D center in Beijing. When the company announced its intention to build the center, it committed $100 million to developing the project over the next five years. The China facility will concentrate on evaluating genetic modifications for [...]

On November 30th, China’s MoHRSS (Ministry of Human Resources and Social Security) released the 2009 version of the National Drug Reimbursement List, which includes 260 new drugs, bringing it to a total of 2151 products. In the new list, all 307 members of the Essential Drug List are automatically included in the A class, which [...]

CRO Industry Draws Biomedical Investors to Asia
Battered by economic uncertainty and under pressure to deliver better medical products in more cost-effective ways, pharmaceutical companies are increasingly driven to outsource their research and development to clinical research organisations (CROs) in Asia. This trend in the biomedical sector is poised to make China one of the most [...]

Beijing, China, December 9, 2009 – China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) (“Nuokang” or the “Company”), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products, announced today that its initial public offering of 5,000,000 American Depositary Shares (“ADSs”), each representing eight ordinary shares of the [...]